Less than a tenth of patients who could benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it publishes its first guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The new guidelines recognises that obesity is a chronic disease that can be managed with comprehensive and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major hurdles to widespread access to the injections that can help people shift considerable body mass, notes the body.
Skinny Jab Scarcity
Even under the current best projected outlook, the production of GLP-1 therapies might only reach around 100 million people – less than 10% of those who need them, according to the health organization.
The advice urges countries and companies to expand availability, via approaches including patent sharing.
The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in several nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs mimick a natural hormone to reduce digestion speed, curb appetite and increase feelings of fullness so users reduce food intake.
Patients commonly begin shedding pounds after several weeks of beginning the weekly injections.
Research indicates patients may regain a significant portion within a year of halting the treatment, because their typical food cravings return.
To be above a healthy weight increases your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in countries worldwide and was associated with millions of fatalities worldwide in 2024, according to the health agency.
